Literature DB >> 11796435

Exhaled H(2)O(2) in steady-state bronchiectasis: relationship with cellular composition in induced sputum, spirometry, and extent and severity of disease.

Stelios Loukides1, Demosthenes Bouros, Georgios Papatheodorou, Stephanos Lachanis, Panos Panagou, Nikolaos M Siafakas.   

Abstract

STUDY
OBJECTIVES: To determine the concentration of exhaled H(2)O(2) in patients with bronchiectasis, and to study the relationship between levels of exhaled H(2)O(2), extent of disease, symptoms score, spirometry, and cellular composition obtained from induced sputum; furthermore, to account for possible confounding effects of inhaled corticosteroids (ICS) usage, long-term oral antibiotic treatment, and chronic colonization with Pseudomonas aeruginosa.
DESIGN: Cross-sectional study. PATIENTS: Thirty patients with steady-state bronchiectasis.
RESULTS: Mean (95% confidence interval [CI]) exhaled H(2)O(2) levels were significantly elevated in patients with bronchiectasis compared to normal subjects: 1.1 (0.87 to 1.29) microM vs 0.3 (0.19 to 0.36) microM, respectively (p < 0.0001). Patients treated with ICS had similar values as steroid-naïve patients. The group of patients with P aeruginosa colonization showed a significantly increased concentration of H(2)O(2) compared to the group without P aeruginosa colonization. Patients receiving long-term oral antibiotic treatment had significantly higher values of H(2)O(2) compared to those not receiving antibiotics. There was a significant positive correlation between H(2)O(2) and either the percentage of neutrophils in induced sputum or the extent of the disease as defined by high-resolution CT. A significant negative correlation was found between H(2)O(2) and FEV(1) percent predicted. Finally, there was a significant positive correlation between H(2)O(2) and the symptoms score.
CONCLUSIONS: Patients with bronchiectasis in stable condition showed increased levels of exhaled H(2)O(2). The above-mentioned levels were not decreased either by ICS or long-term oral antibiotic treatment, but were significantly affected by chronic colonization with P aeruginosa. H(2)O(2) levels could be an indirect index of neutrophilic inflammation, impairment of lung function, and extension and severity of the disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11796435     DOI: 10.1378/chest.121.1.81

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  18 in total

1.  Persistent sputum cellularity and neutrophils may predict bronchiectasis.

Authors:  Nicole Drost; Liesel D'silva; Ryan Rebello; Ann Efthimiadis; Frederick E Hargreave; Parameswaran Nair
Journal:  Can Respir J       Date:  2011 Jul-Aug       Impact factor: 2.409

Review 2.  A review of non-cystic fibrosis pediatric bronchiectasis.

Authors:  Eric J Boren; Suzanne S Teuber; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2008-04       Impact factor: 8.667

3.  Lung oxidative stress as related to exercise and altitude. Lipid peroxidation evidence in exhaled breath condensate: a possible predictor of acute mountain sickness.

Authors:  O F Araneda; C García; N Lagos; G Quiroga; J Cajigal; M P Salazar; C Behn
Journal:  Eur J Appl Physiol       Date:  2005-09-30       Impact factor: 3.078

Review 4.  Mechanisms and function of DUOX in epithelia of the lung.

Authors:  Horst Fischer
Journal:  Antioxid Redox Signal       Date:  2009-10       Impact factor: 8.401

5.  Low-dose clarithromycin therapy modulates Th17 response in non-cystic fibrosis bronchiectasis patients.

Authors:  Evangelia Fouka; Eleftheria Lamprianidou; Konstantinos Arvanitidis; Eirini Filidou; George Kolios; Paraskevi Miltiades; Emmanouil Paraskakis; Antonios Antoniadis; Ioannis Kotsianidis; Demosthenes Bouros
Journal:  Lung       Date:  2014-07-14       Impact factor: 2.584

6.  Hydrogen peroxide release and acid-base status in exhaled breath condensate at rest and after maximal exercise in young, healthy subjects.

Authors:  E Marek; P Platen; J Volke; K Mückenhoff; W Marek
Journal:  Eur J Med Res       Date:  2009-12-07       Impact factor: 2.175

Review 7.  The pathophysiology of bronchiectasis.

Authors:  Paul T King
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-11-29

8.  The immune response and its therapeutic modulation in bronchiectasis.

Authors:  Massoud Daheshia; James D Prahl; Jacob J Carmichael; John S Parrish; Gilbert Seda
Journal:  Pulm Med       Date:  2012-10-10

9.  Matrix metalloproteinase-1 polymorphism (-1607G) and disease severity in non-cystic fibrosis bronchiectasis in Taiwan.

Authors:  Meng-Heng Hsieh; Pai-Chien Chou; Chun-Liang Chou; Shu-Chuan Ho; Wen-Ching Joa; Li-Fei Chen; Te-Fang Sheng; Horng-Chyuan Lin; Tsai-Yu Wang; Po-Jui Chang; Chun-Hua Wang; Han-Pin Kuo
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

Review 10.  The role of macrolides in childhood non-cystic fibrosis-related bronchiectasis.

Authors:  R Masekela; R J Green
Journal:  Mediators Inflamm       Date:  2012-04-18       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.